So it was never going to fly? Were MSB that pig headed in your...

First 1038 Last

Share
Profile

Follow
stocksa

7,965 Posts.

635

09/04/21

10:49

Post #: 52353119
Share

Originally posted by Southoz ↑

Hi Stanjupier – very quickly – in response to a couple of questions you have asked me.

At the AdCom meeting no-one (not the experts, FDA or MSB) expressed any difficulty with designing a RCT for adults with GvHD.

According to MSB they were well advanced in the design of the adult study and had been in discussion with centres to take part in the study.

If you are interested in what the design of the study that MSB are proposing the best bet would be to ask MSB. Not me or Davisite.

In terms of MSB leaving no stone unturned to avoid another trial? This is a little bit of a no-brainer. In 17 years and a couple of dozen RCTs MSB have never met a per-specified endpoint – for anything. When you don’t meet per-specified endpoints in trials this is very problematic. In the context here … it would be fatal for approval.

“Southoz has said the FDA wanted matching at the patient level. I take it that means ensuring the characteristics are balanced between groups in a RCT?”

No – you are misunderstanding this point.

The FDA rejected MSBs approach to deriving the control group estimate in the single arm GvHD trial. The FDA asked MSB to provide further justification for the control group estimate and so MSB conducted the MAGIC study.

The MAGIC study essentially went okay lets match at a group level patients from the MAGIC database with patients who were in the single arm trial. So that at the end of this process on key prognostic factors you would have a rough equivalence – eg both groups would have a similar average age.

The FDA rejected this approach. What it wanted was MSB to match at the individual level – a case control study. That is if the single arm study had a child 10 years old with prognostic factors XYZ find a similar child in the MAGIC database to match to. And to do this within a confirmatory framework – that is pre-specify the “control” endpoint estimate.

According to the FDA the reason this misunderstanding of what they wanted and what MSB did occurred because MSB failed to submit its statistical analysis plan to them. So the MAGIC study turned out to be a waste of money – it didn’t convince the FDA of anything.

This mistake in MAGIC, together with the error that MSB had made in its original approach to the control group estimate and the totality of the negative evidence from 17 years worth of methodologically stronger (RCTs) trials - meant game over for MSB - despite the 9:1 vote.

Expand

So it was never going to fly?
Were MSB that pig headed in your viewpoint?
How do they solve it....if that is possible?
I am open to any trial that gets us over the line We need to bite the bullet

Last edited by stocksa: 09/04/21

MSB Price at posting: $2.24 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Making money: How many microcaps should be in an investor's portfolio?

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Finance school vs reality: What they don't teach you about the stock market

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 38 more messages in this thread...

First 1038 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.31		Change 0.040(3.16%)		Mkt cap ! $1.490B

Open	High	Low	Value	Volume
$1.28	$1.32	$1.26	$3.433M	2.652M

Buyers (Bids)

No.	Vol.	Price($)
2	39558	$1.30

Sellers (Offers)

Price($)	Vol.	No.
$1.31	21776	3

View Market Depth

No.	Vol.	Price($)
2	39558	1.300
3	26433	1.295
6	108207	1.290
2	47468	1.285
3	10889	1.280

Price($)	Vol.	No.
1.310	21776	3
1.315	57441	5
1.320	2500	1
1.325	61160	4
1.330	15000	2

Last trade - 16.10pm 28/10/2024 (20 minute delay)

MSB (ASX) Chart

So it was never going to fly? Were MSB that pig headed in your...

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Making money: How many microcaps should be in an investor's portfolio?

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Finance school vs reality: What they don't teach you about the stock market

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

So it was never going to fly? Were MSB that pig headed in your...

Top Stories

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Making money: How many microcaps should be in an investor's portfolio?

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Finance school vs reality: What they don't teach you about the stock market

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News